6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
10 O
% O
) O
- O
infections O
( O
e.g O
. O

upper O
respiratory O
, O
sinusitis O
, O
and O
pharyngitis O
) O
, O
infusion-related O
reactions O
, O
headache O
, O
and O
abdominal O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Biotech O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
in O
Adults O
The O
data O
described O
herein O
reflect O
exposure O
to O
REMICADE O
in O
4779 O
adult O
patients O
( O
1304 O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1106 O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
202 O
with O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
293 O
with O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
484 O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
1373 O
with O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
and O
17 O
patients O
with O
other O
conditions O
) O
, O
including O
2625 O
patients O
exposed O
beyond O
30 O
weeks O
and O
374 O
exposed O
beyond O
1 O
year O
. O

[ O
For O
information O
on O
adverse O
reactions O
in O
pediatric O
patients O
see O
Adverse O
Reactions O
( O
6.1 O
) O
. O
] O

One O
of O
the O
most-common O
reasons O
for O
discontinuation O
of O
treatment O
was O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
dyspnea B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
) O
. O

Infusion-related O
Reactions O
An O
infusion O
reaction O
was O
defined O
in O
clinical O
trials O
as O
any O
adverse O
event O
occurring O
during O
an O
infusion O
or O
within O
1 O
hour O
after O
an O
infusion O
. O

In O
Phase O
3 O
clinical O
studies O
, O
18 O
% O
of O
REMICADE-treated O
patients O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
compared O
to O
5 O
% O
of O
placebo-treated O
patients O
. O

Of O
infliximab-treated O
patients O
who O
had O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
induction O
period O
, O
27 O
% O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
maintenance O
period O
. O

Of O
patients O
who O
did O
not O
have O
an O
infusion O
reaction O
during O
the O
induction O
period O
, O
9 O
% O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
maintenance O
period O
. O

Among O
all O
REMICADE O
infusions O
, O
3 O
% O
were O
accompanied O
by O
nonspecific O
symptoms O
such O
as O
fever B-OSE_Labeled_AE
or O
chills B-OSE_Labeled_AE
, O
1 O
% O
were O
accompanied O
by O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
primarily O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
or O
dyspnea B-OSE_Labeled_AE
) O
, O
and O
< O
1 O
% O
were O
accompanied O
by O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
or O
the O
combined O
symptoms O
of O
pruritus B-OSE_Labeled_AE
/ O
urticaria B-OSE_Labeled_AE
and O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
of O
patients O
and O
included O
anaphylaxis B-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
, O
erythematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
hypotension B-OSE_Labeled_AE
. O

Approximately O
3 O
% O
of O
patients O
discontinued O
REMICADE O
because O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
all O
patients O
recovered O
with O
treatment O
and/or O
discontinuation O
of O
the O
infusion O
. O

REMICADE O
infusions O
beyond O
the O
initial O
infusion O
were O
not O
associated O
with O
a O
higher O
incidence O
of O
reactions O
. O

The O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates O
remained O
stable O
in O
psoriasis B-Not_AE_Candidate
through O
1 O
year O
in O
psoriasis B-Not_AE_Candidate
Study O
I O
. O

In O
psoriasis B-Not_AE_Candidate
Study O
II O
, O
the O
rates O
were O
variable O
over O
time O
and O
somewhat O
higher O
following O
the O
final O
infusion O
than O
after O
the O
initial O
infusion O
. O

Across O
the O
3 O
psoriasis B-Not_AE_Candidate
studies O
, O
the O
percent O
of O
total O
infusions O
resulting O
in O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
i.e. O
, O
an O
adverse O
event O
occurring O
within O
1 O
hour O
) O
was O
7 O
% O
in O
the O
3 O
mg/kg O
group O
, O
4 O
% O
in O
the O
5 O
mg/kg O
group O
, O
and O
1 O
% O
in O
the O
placebo O
group O
. O

Patients O
who O
became O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
were O
more O
likely O
( O
approximately O
two-to O
three-fold O
) O
to O
have O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
than O
were O
those O
who O
were O
negative O
. O

Use O
of O
concomitant O
immunosuppressant B-NonOSE_AE
agents I-NonOSE_AE
appeared O
to O
reduce O
the O
frequency O
of O
both O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Infusion O
Reactions O
Following O
Re-administration O
In O
a O
clinical O
trial O
of O
patients O
with O
moderate O
to O
severe O
psoriasis B-Not_AE_Candidate
designed O
to O
assess O
the O
efficacy O
of O
long-term O
maintenance O
therapy O
versus O
re-treatment O
with O
an O
induction O
regimen O
of O
REMICADE O
following O
disease O
flare O
, O
4 O
% O
( O
8/219 O
) O
of O
patients O
in O
the O
re-treatment O
therapy O
arm O
experienced O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
versus O
< O
1 O
% O
( O
1/222 O
) O
in O
the O
maintenance O
therapy O
arm O
. O

Patients O
enrolled O
in O
this O
trial O
did O
not O
receive O
any O
concomitant O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
. O

In O
this O
study O
, O
the O
majority O
of O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
during O
the O
second O
infusion O
at O
Week O
2 O
. O

Symptoms O
included O
, O
but O
were O
not O
limited O
to O
, O
dyspnea B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
facial B-NonOSE_AE
edema I-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

In O
all O
cases O
, O
REMICADE O
treatment O
was O
discontinued O
and/or O
other O
treatment O
instituted O
with O
complete O
resolution O
of O
signs O
and O
symptoms O
. O

Delayed O
Reactions/Reactions O
Following O
Re-administration O
In O
psoriasis B-Not_AE_Candidate
studies O
, O
approximately O
1 O
% O
of O
REMICADE-treated O
patients O
experienced O
a O
possible O
delayed B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
generally O
reported O
as O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
or O
a O
combination O
of O
arthralgia B-OSE_Labeled_AE
and/or O
myalgia B-OSE_Labeled_AE
with O
fever B-OSE_Labeled_AE
and/or O
rash B-OSE_Labeled_AE
. O

These O
reactions O
generally O
occurred O
within O
2 O
weeks O
after O
repeat O
infusion O
. O

Infections O
In O
REMICADE O
clinical O
studies O
, O
treated O
infections B-OSE_Labeled_AE
were O
reported O
in O
36 O
% O
of O
REMICADE-treated O
patients O
( O
average O
of O
51 O
weeks O
of O
follow-up O
) O
and O
in O
25 O
% O
of O
placebo-treated O
patients O
( O
average O
of O
37 O
weeks O
of O
follow-up O
) O
. O

The O
infections B-OSE_Labeled_AE
most O
frequently O
reported O
were O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
sinusitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
) O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Among O
REMICADE-treated O
patients O
, O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
bacterial B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

In O
clinical O
trials O
, O
7 O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
were O
reported O
; O
2 O
cases O
each O
of O
coccidioidomycosis B-OSE_Labeled_AE
( O
1 O
case O
was O
fatal B-NonOSE_AE
) O
and O
histoplasmosis B-OSE_Labeled_AE
( O
1 O
case O
was O
fatal B-NonOSE_AE
) O
, O
and O
1 O
case O
each O
of O
pneumocystosis B-OSE_Labeled_AE
, O
nocardiosis B-OSE_Labeled_AE
and O
cytomegalovirus B-OSE_Labeled_AE
. O

Tuberculosis B-OSE_Labeled_AE
was O
reported O
in O
14 O
patients O
, O
4 O
of O
whom O
died B-NonOSE_AE
due O
to O
miliary B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Other O
cases O
of O
tuberculosis B-OSE_Labeled_AE
, O
including O
disseminated B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
also O
have O
been O
reported O
post-marketing O
. O

Most O
of O
these O
cases O
of O
tuberculosis B-OSE_Labeled_AE
occurred O
within O
the O
first O
2 O
months O
after O
initiation O
of O
therapy O
with O
REMICADE O
and O
may O
reflect O
recrudescence B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
disease I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
the O
1-year O
placebo-controlled O
studies O
RA B-Not_AE_Candidate
I O
and O
RA B-Not_AE_Candidate
II O
, O
5.3 O
% O
of O
patients O
receiving O
REMICADE O
every O
8 O
weeks O
with O
MTX O
developed O
serious O
infections B-OSE_Labeled_AE
as O
compared O
to O
3.4 O
% O
of O
placebo O
patients O
receiving O
MTX O
. O

Of O
924 O
patients O
receiving O
REMICADE O
, O
1.7 O
% O
developed O
pneumonia B-OSE_Labeled_AE
and O
0.4 O
% O
developed O
TB B-OSE_Labeled_AE
, O
when O
compared O
to O
0.3 O
% O
and O
0.0 O
% O
in O
the O
placebo O
arm O
respectively O
. O

In O
a O
shorter O
( O
22-week O
) O
placebo-controlled O
study O
of O
1082 O
RA B-Not_AE_Candidate
patients O
randomized O
to O
receive O
placebo O
, O
3 O
mg/kg O
or O
10 O
mg/kg O
REMICADE O
infusions O
at O
0 O
, O
2 O
, O
and O
6 O
weeks O
, O
followed O
by O
every O
8 O
weeks O
with O
MTX O
, O
serious O
infections B-OSE_Labeled_AE
were O
more O
frequent O
in O
the O
10 O
mg/kg O
REMICADE O
group O
( O
5.3 O
% O
) O
than O
the O
3 O
mg/kg O
or O
placebo O
groups O
( O
1.7 O
% O
in O
both O
) O
. O

During O
the O
54-week O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
II O
Study O
, O
15 O
% O
of O
patients O
with O
fistulizing B-Not_AE_Candidate
Crohn I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
developed O
a O
new O
fistula B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
. O

In O
REMICADE O
clinical O
studies O
in O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
treated O
with O
antimicrobials O
were O
reported O
in O
27 O
% O
of O
REMICADE-treated O
patients O
( O
average O
of O
41 O
weeks O
of O
follow-up O
) O
and O
in O
18 O
% O
of O
placebo-treated O
patients O
( O
average O
32 O
weeks O
of O
follow-up O
) O
. O

The O
types O
of O
infections B-NonOSE_AE
, O
including O
serious O
infections B-NonOSE_AE
, O
reported O
in O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
were O
similar O
to O
those O
reported O
in O
other O
clinical O
studies O
. O

The O
onset O
of O
serious O
infections B-NonOSE_AE
may O
be O
preceded O
by O
constitutional O
symptoms O
such O
as O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
weight B-NonOSE_AE
loss I-NonOSE_AE
, O
and O
fatigue B-NonOSE_AE
. O

The O
majority O
of O
serious O
infections B-NonOSE_AE
, O
however O
, O
may O
also O
be O
preceded O
by O
signs O
or O
symptoms O
localized O
to O
the O
site O
of O
the O
infection B-NonOSE_AE
. O

Autoantibodies/Lupus-like O
Syndrome O
Approximately O
half O
of O
REMICADE-treated O
patients O
in O
clinical O
trials O
who O
were O
antinuclear B-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
ANA I-Not_AE_Candidate
) I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
developed O
a O
positive B-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
during O
the O
trial O
compared O
with O
approximately O
one-fifth O
of O
placebo-treated O
patients O
. O

Anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dsDNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
newly O
detected O
in O
approximately O
one-fifth O
of O
REMICADE-treated O
patients O
compared O
with O
0 O
% O
of O
placebo-treated O
patients O
. O

Reports O
of O
lupus B-OSE_Labeled_AE
and O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
however O
, O
remain O
uncommon O
. O

Malignancies O
In O
controlled O
trials O
, O
more O
REMICADE-treated O
patients O
developed O
malignancies B-OSE_Labeled_AE
than O
placebo-treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

In O
a O
randomized O
controlled O
clinical O
trial O
exploring O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
COPD B-Not_AE_Candidate
who O
were O
either O
current O
smokers O
or O
ex-smokers O
, O
157 O
patients O
were O
treated O
with O
REMICADE O
at O
doses O
similar O
to O
those O
used O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Of O
these O
REMICADE-treated O
patients O
, O
9 O
developed O
a O
malignancy B-OSE_Labeled_AE
, O
including O
1 O
lymphoma B-OSE_Labeled_AE
, O
for O
a O
rate O
of O
7.67 O
cases O
per O
100 O
patient-years O
of O
follow-up O
( O
median O
duration O
of O
follow-up O
0.8 O
years O
; O
95 O
% O
CI O
3.51 O
- O
14.56 O
) O
. O

There O
was O
1 O
reported O
malignancy B-OSE_Labeled_AE
among O
77 O
control O
patients O
for O
a O
rate O
of O
1.63 O
cases O
per O
100 O
patient-years O
of O
follow-up O
( O
median O
duration O
of O
follow-up O
0.8 O
years O
; O
95 O
% O
CI O
0.04 O
- O
9.10 O
) O
. O

The O
majority O
of O
the O
malignancies B-OSE_Labeled_AE
developed I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lung I-OSE_Labeled_AE
or O
head O
and O
neck O
. O

Patients O
with O
Heart O
Failure O
In O
a O
randomized O
study O
evaluating O
REMICADE O
in O
moderate O
to O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
/IV O
; O
left B-Not_AE_Candidate
ventricular I-Not_AE_Candidate
ejection I-Not_AE_Candidate
fraction I-Not_AE_Candidate
< I-Not_AE_Candidate
= I-Not_AE_Candidate
3 I-Not_AE_Candidate
5 I-Not_AE_Candidate
% I-Not_AE_Candidate
) O
, O
150 O
patients O
were O
randomized O
to O
receive O
treatment O
with O
3 O
infusions O
of O
REMICADE O
10 O
mg/kg O
, O
5 O
mg/kg O
, O
or O
placebo O
, O
at O
0 O
, O
2 O
, O
and O
6 O
weeks O
. O

Higher O
incidences O
of O
mortality B-NonOSE_AE
and O
hospitalization O
due O
to O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
were O
observed O
in O
patients O
receiving O
the O
10 O
mg/kg O
REMICADE O
dose O
. O

At O
1 O
year O
, O
8 O
patients O
in O
the O
10 O
mg/kg O
REMICADE O
group O
had O
died B-NonOSE_AE
compared O
with O
4 O
deaths B-NonOSE_AE
each O
in O
the O
5 O
mg/kg O
REMICADE O
and O
the O
placebo O
groups O
. O

There O
were O
trends O
toward O
increased O
dyspnea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
in O
both O
the O
10 O
mg/kg O
and O
5 O
mg/kg O
REMICADE O
treatment O
groups O
, O
versus O
placebo O
. O

REMICADE O
has O
not O
been O
studied O
in O
patients O
with O
mild O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Class I-Not_AE_Candidate
I I-Not_AE_Candidate
/II O
) O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Immunogenicity O
Treatment O
with O
REMICADE O
can O
be O
associated O
with O
the O
development O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

An O
enzyme O
immunoassay O
( O
EIA O
) O
method O
was O
originally O
used O
to O
measure O
anti B-NonOSE_AE
- I-NonOSE_AE
infliximab I-NonOSE_AE
antibodies I-NonOSE_AE
in O
clinical O
studies O
of O
REMICADE O
. O

The O
EIA O
method O
is O
subject O
to O
interference O
by O
serum O
infliximab O
, O
possibly O
resulting O
in O
an O
underestimation O
of O
the O
rate O
of O
patient O
antibody B-NonOSE_AE
formation I-NonOSE_AE
. O

A O
separate O
, O
drug-tolerant O
electrochemiluminescence O
immunoassay O
( O
ECLIA O
) O
method O
for O
detecting O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
subsequently O
developed O
and O
validated O
. O

This O
method O
is O
60-fold O
more O
sensitive O
than O
the O
original O
EIA O
. O

With O
the O
ECLIA O
method O
, O
all O
clinical O
samples O
can O
be O
classified O
as O
either O
positive O
or O
negative O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
without O
the O
need O
for O
the O
inconclusive O
category O
. O

The O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
based O
on O
the O
original O
EIA O
method O
in O
all O
clinical O
studies O
of O
REMICADE O
except O
for O
the O
Phase O
3 O
study O
in O
pediatric O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
where O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
detected O
using O
both O
the O
EIA O
and O
ECLIA O
methods O
[ O
see O
Adverse O
Reactions O
, O
Pediatric O
Ulcerative B-Not_AE_Candidate
Colitis I-Not_AE_Candidate
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
in O
patients O
given O
a O
3-dose O
induction O
regimen O
followed O
by O
maintenance O
dosing O
was O
approximately O
10 O
% O
as O
assessed O
through O
1 O
to O
2 O
years O
of O
REMICADE O
treatment O
. O

A O
higher O
incidence O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
was O
observed O
in O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
REMICADE O
after O
drug-free O
intervals O
> O
16 O
weeks O
. O

In O
a O
study O
of O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
in O
which O
191 O
patients O
received O
5 O
mg/kg O
with O
or O
without O
MTX O
, O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
patients O
. O

The O
majority O
of O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
patients O
had O
low O
titers O
. O

Patients O
who O
were O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
were O
more O
likely O
to O
have O
higher O
rates O
of O
clearance O
, O
reduced O
efficacy O
and O
to O
experience O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
than O
were O
patients O
who O
were O
antibody B-NonOSE_AE
negative I-NonOSE_AE
. O

Antibody B-OSE_Labeled_AE
development O
was O
lower O
among O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
such O
as O
6-MP/AZA O
or O
MTX O
. O

In O
the O
psoriasis B-Not_AE_Candidate
Study O
II O
, O
which O
included O
both O
the O
5 O
mg/kg O
and O
3 O
mg/kg O
doses O
, O
antibodies B-OSE_Labeled_AE
were O
observed O
in O
36 O
% O
of O
patients O
treated O
with O
5 O
mg/kg O
every O
8 O
weeks O
for O
1 O
year O
, O
and O
in O
51 O
% O
of O
patients O
treated O
with O
3 O
mg/kg O
every O
8 O
weeks O
for O
1 O
year O
. O

In O
the O
psoriasis B-Not_AE_Candidate
Study O
III O
, O
which O
also O
included O
both O
the O
5 O
mg/kg O
and O
3 O
mg/kg O
doses O
, O
antibodies B-OSE_Labeled_AE
were O
observed O
in O
20 O
% O
of O
patients O
treated O
with O
5 O
mg/kg O
induction O
( O
weeks O
0 O
, O
2 O
and O
6 O
) O
, O
and O
in O
27 O
% O
of O
patients O
treated O
with O
3 O
mg/kg O
induction O
. O

Despite O
the O
increase B-NonOSE_AE
in I-NonOSE_AE
antibody I-NonOSE_AE
formation O
, O
the O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates I-NonOSE_AE
in O
Studies O
I O
and O
II O
in O
patients O
treated O
with O
5 O
mg/kg O
induction O
followed O
by O
every O
8 O
week O
maintenance O
for O
1 O
year O
and O
in O
Study O
III O
in O
patients O
treated O
with O
5 O
mg/kg O
induction O
( O
14.1 O
% O
-23.0 O
% O
) O
and O
serious O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates O
( O
< O
1 O
% O
) O
were O
similar O
to O
those O
observed O
in O
other O
study O
populations O
. O

The O
clinical O
significance O
of O
apparent O
increased O
immunogenicity B-NonOSE_AE
on O
efficacy O
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
psoriasis B-Not_AE_Candidate
patients O
as O
compared O
to O
patients O
with O
other O
diseases O
treated O
with O
REMICADE O
over O
the O
long O
term O
is O
not O
known O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
in O
an O
immunoassay O
, O
and O
they O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

Hepatotoxicity B-OSE_Labeled_AE
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
has O
been O
reported O
in O
patients O
receiving O
REMICADE O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
has O
occurred O
in O
patients O
receiving O
TNF-blocking O
agents O
, O
including O
REMICADE O
, O
who O
are O
chronic O
carriers O
of O
this O
virus O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

In O
clinical O
trials O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
and O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
aminotransferases I-OSE_Labeled_AE
were O
observed O
( O
ALT O
more O
common O
than O
AST O
) O
in O
a O
greater O
proportion O
of O
patients O
receiving O
REMICADE O
than O
in O
controls O
( O
Table O
1 O
) O
, O
both O
when O
REMICADE O
was O
given O
as O
monotherapy O
and O
when O
it O
was O
used O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

In O
general O
, O
patients O
who O
developed O
ALT B-OSE_Labeled_AE
and O
AST O
elevations I-OSE_Labeled_AE
were O
asymptomatic O
, O
and O
the O
abnormalities O
decreased O
or O
resolved O
with O
either O
continuation O
or O
discontinuation O
of O
REMICADE O
, O
or O
modification O
of O
concomitant O
medications O
. O

Table O
1 O
: O
Proportion O
of O
patients O
with O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
in O
clinical O
trials O
Proportion O
of O
patients O
with O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
> O
1 O
to O
< O
3 O
* O
ULN O
> O
=3 O
* O
ULN O
> O
=5 O
* O
ULN O
Placebo O
REMICADE O
Placebo O
REMICADE O
Placebo O
REMICADE O
Rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
[ O
note O
: O
Placebo O
patients O
received O
methotrexate O
while O
REMICADE O
patients O
received O
both O
REMICADE O
and O
methotrexate O
. O

Median O
follow-up O
was O
58 O
weeks O
. O
] O

24 O
% O
34 O
% O
3 O
% O
4 O
% O
< O
1 O
% O
< O
1 O
% O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ O
note O
: O
Placebo O
patients O
in O
the O
2 O
Phase O
3 O
trials O
in O
Crohn O
's O
disease O
received O
an O
initial O
dose O
of O
5 O
mg/kg O
REMICADE O
at O
study O
start O
and O
were O
on O
placebo O
in O
the O
maintenance O
phase O
. O

Patients O
who O
were O
randomized O
to O
the O
placebo O
maintenance O
group O
and O
then O
later O
crossed O
over O
to O
REMICADE O
are O
included O
in O
the O
REMICADE O
group O
in O
ALT O
analysis O
. O

Median O
follow-up O
was O
54 O
weeks O
. O
] O

34 O
% O
39 O
% O
4 O
% O
5 O
% O
0 O
% O
2 O
% O
Ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
30 O
weeks O
. O

Specifically O
, O
the O
median O
duration O
of O
follow-up O
was O
30 O
weeks O
for O
placebo O
and O
31 O
weeks O
for O
REMICADE O
. O
] O

12 O
% O
17 O
% O
1 O
% O
2 O
% O
< O
1 O
% O
< O
1 O
% O
Ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
24 O
weeks O
for O
the O
placebo O
group O
and O
102 O
weeks O
for O
the O
REMICADE O
group O
. O
] O

15 O
% O
51 O
% O
0 O
% O
10 O
% O
0 O
% O
4 O
% O
Psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
39 O
weeks O
for O
the O
REMICADE O
group O
and O
18 O
weeks O
for O
the O
placebo O
group O
. O
] O

16 O
% O
50 O
% O
0 O
% O
7 O
% O
0 O
% O
2 O
% O
Plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
[ O
note O
: O
ALT O
values O
are O
obtained O
in O
2 O
Phase O
3 O
psoriasis O
studies O
with O
median O
follow-up O
of O
50 O
weeks O
for O
REMICADE O
and O
16 O
weeks O
for O
placebo O
. O
] O

24 O
% O
49 O
% O
< O
1 O
% O
8 O
% O
0 O
% O
3 O
% O
Adverse O
Reactions O
in O
Psoriasis O
Studies O
During O
the O
placebo-controlled O
portion O
across O
the O
3 O
clinical O
trials O
up O
to O
Week O
16 O
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
1 O
serious O
adverse O
reaction O
( O
SAE O
; O
defined O
as O
resulting O
in O
death B-NonOSE_AE
, O
life O
threatening O
, O
requires O
hospitalization O
, O
or O
persistent O
or O
significant O
disability/incapacity O
) O
was O
0.5 O
% O
in O
the O
3 O
mg/kg O
REMICADE O
group O
, O
1.9 O
% O
in O
the O
placebo O
group O
, O
and O
1.6 O
% O
in O
the O
5 O
mg/kg O
REMICADE O
group O
. O

Among O
patients O
in O
the O
2 O
Phase O
3 O
studies O
, O
12.4 O
% O
of O
patients O
receiving O
REMICADE O
5 O
mg/kg O
every O
8 O
weeks O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
SAE O
in O
Study O
I O
. O

In O
Study O
II O
, O
4.1 O
% O
and O
4.7 O
% O
of O
patients O
receiving O
REMICADE O
3 O
mg/kg O
and O
5 O
mg/kg O
every O
8 O
weeks O
, O
respectively O
, O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
SAE O
. O

One O
death B-NonOSE_AE
due O
to O
bacterial B-NonOSE_AE
sepsis I-NonOSE_AE
occurred O
25 O
days O
after O
the O
second O
infusion O
of O
5 O
mg/kg O
REMICADE O
. O

Serious O
infections B-OSE_Labeled_AE
included O
sepsis B-OSE_Labeled_AE
, O
and O
abscesses B-OSE_Labeled_AE
. O

In O
Study O
I O
, O
2.7 O
% O
of O
patients O
receiving O
REMICADE O
5 O
mg/kg O
every O
8 O
weeks O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
serious O
infection B-OSE_Labeled_AE
. O

In O
Study O
II O
, O
1.0 O
% O
and O
1.3 O
% O
of O
patients O
receiving O
REMICADE O
3 O
mg/kg O
and O
5 O
mg/kg O
, O
respectively O
, O
through O
1 O
year O
of O
treatment O
experienced O
at O
least O
1 O
serious O
infection B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
infection B-NonOSE_AE
( O
requiring O
hospitalization O
) O
was O
abscess B-OSE_Labeled_AE
( O
skin O
, O
throat O
, O
and O
peri-rectal O
) O
reported O
by O
5 O
( O
0.7 O
% O
) O
patients O
in O
the O
5 O
mg/kg O
REMICADE O
group O
. O

Two O
active O
cases O
of O
tuberculosis B-OSE_Labeled_AE
were O
reported O
: O
6 O
weeks O
and O
34 O
weeks O
after O
starting O
REMICADE O
. O

In O
the O
placebo-controlled O
portion O
of O
the O
psoriasis B-Not_AE_Candidate
studies O
, O
7 O
of O
1123 O
patients O
who O
received O
REMICADE O
at O
any O
dose O
were O
diagnosed O
with O
at O
least O
one O
NMSC B-OSE_Labeled_AE
compared O
to O
0 O
of O
334 O
patients O
who O
received O
placebo O
. O

In O
the O
psoriasis B-Not_AE_Candidate
studies O
, O
1 O
% O
( O
15/1373 O
) O
of O
patients O
experienced O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
or O
a O
combination O
of O
arthralgia B-OSE_Labeled_AE
and/or O
myalgia B-OSE_Labeled_AE
with O
fever B-OSE_Labeled_AE
, O
and/or O
rash B-OSE_Labeled_AE
, O
usually O
early O
in O
the O
treatment O
course O
. O

Of O
these O
patients O
, O
6 O
required O
hospitalization O
due O
to O
fever B-OSE_Labeled_AE
, O
severe O
myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
swollen B-OSE_Labeled_AE
joints I-OSE_Labeled_AE
, O
and O
immobility B-OSE_Labeled_AE
. O

Other O
Adverse O
Reactions O
Safety O
data O
are O
available O
from O
4779 O
REMICADE-treated O
adult O
patients O
, O
including O
1304 O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1106 O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
484 O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
202 O
with O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
293 O
with O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1373 O
with O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
and O
17 O
with O
other O
conditions O
. O

[ O
For O
information O
on O
other O
adverse O
reactions O
in O
pediatric O
patients O
, O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
all O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
receiving O
4 O
or O
more O
infusions O
are O
in O
Table O
2 O
. O

The O
types O
and O
frequencies O
of O
adverse O
reactions O
observed O
were O
similar O
in O
REMICADE-treated O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
except O
for O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
which O
occurred O
in O
26 O
% O
of O
REMICADE-treated O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
the O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
studies O
, O
there O
were O
insufficient O
numbers O
and O
duration O
of O
follow-up O
for O
patients O
who O
never O
received O
REMICADE O
to O
provide O
meaningful O
comparisons O
. O

Table O
2 O
: O
Adverse O
reactions O
occurring O
in O
5 O
% O
or O
more O
of O
patients O
receiving O
4 O
or O
more O
infusions O
for O
rheumatoid O
arthritis O
Placebo O
REMICADE O
( O
n=350 O
) O
( O
n=1129 O
) O
Average O
weeks O
of O
follow-up O
59 O
66 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
20 O
% O
21 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
8 O
% O
12 O
% O
Diarrhea B-NonOSE_AE
12 O
% O
12 O
% O
Dyspepsia B-OSE_Labeled_AE
7 O
% O
10 O
% O
Respiratory B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
25 O
% O
32 O
% O
Sinusitis B-OSE_Labeled_AE
8 O
% O
14 O
% O
Pharyngitis B-OSE_Labeled_AE
8 O
% O
12 O
% O
Coughing B-OSE_Labeled_AE
8 O
% O
12 O
% O
Bronchitis B-OSE_Labeled_AE
9 O
% O
10 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
5 O
% O
10 O
% O
Pruritus B-OSE_Labeled_AE
2 O
% O
7 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- I-NonOSE_AE
general I-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
7 O
% O
9 O
% O
Pain B-OSE_Labeled_AE
7 O
% O
8 O
% O
Resistance B-NonOSE_AE
mechanism I-NonOSE_AE
disorders I-NonOSE_AE
Fever B-OSE_Labeled_AE
4 O
% O
7 O
% O
Moniliasis B-OSE_Labeled_AE
3 O
% O
5 O
% O
Central B-NonOSE_AE
and I-NonOSE_AE
peripheral I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
14 O
% O
18 O
% O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
7 O
% O
8 O
% O
Urinary B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
% O
8 O
% O
Cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
, I-NonOSE_AE
general I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
5 O
% O
7 O
% O
The O
most O
common O
serious O
adverse O
reactions O
observed O
in O
clinical O
trials O
were O
infections B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Other O
serious O
, O
medically O
relevant O
adverse O
reactions O
> O
=0.2 O
% O
or O
clinically O
significant O
adverse O
reactions O
by O
body O
system O
were O
as O
follows O
: O
* O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
: O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
* O
Blood B-NonOSE_AE
: O
pancytopenia B-OSE_Labeled_AE
* O
Cardiovascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
: O
constipation B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
* O
Central B-NonOSE_AE
and I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
: O
dizziness B-OSE_Labeled_AE
* O
Heart B-NonOSE_AE
Rate I-NonOSE_AE
and I-NonOSE_AE
Rhythm I-NonOSE_AE
: O
bradycardia B-OSE_Labeled_AE
* O
Liver B-NonOSE_AE
and I-NonOSE_AE
Biliary I-NonOSE_AE
: O
hepatitis B-OSE_Labeled_AE
* O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
* O
Platelet B-NonOSE_AE
, I-NonOSE_AE
Bleeding I-NonOSE_AE
and I-NonOSE_AE
Clotting I-NonOSE_AE
: O
thrombocytopenia B-OSE_Labeled_AE
* O
Neoplasms B-NonOSE_AE
: O
lymphoma B-OSE_Labeled_AE
* O
Red B-NonOSE_AE
Blood I-NonOSE_AE
Cell I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
* O
Resistance B-NonOSE_AE
Mechanism I-NonOSE_AE
: O
cellulitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
, O
sarcoidosis B-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
: O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
including O
pneumonia B-OSE_Labeled_AE
) O
, O
pleurisy B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
sweating I-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
( I-NonOSE_AE
Extracardiac I-NonOSE_AE
) O
: O
thrombophlebitis B-OSE_Labeled_AE
* O
White B-NonOSE_AE
Cell I-NonOSE_AE
and I-NonOSE_AE
Reticuloendothelial I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
Adverse O
Reactions O
in O
Pediatric O
Patients O
Pediatric O
Crohn O
's O
Disease O
There O
were O
some O
differences O
in O
the O
adverse O
reactions O
observed O
in O
the O
pediatric O
patients O
receiving O
REMICADE O
compared O
to O
those O
observed O
in O
adults O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

These O
differences O
are O
discussed O
in O
the O
following O
paragraphs O
. O

The O
following O
adverse O
reactions O
were O
reported O
more O
commonly O
in O
103 O
randomized O
pediatric O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
administered O
5 O
mg/kg O
REMICADE O
through O
54 O
weeks O
than O
in O
385 O
adult O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
a O
similar O
treatment O
regimen O
: O
anemia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
flushing B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
bone B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
bacterial B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Infections B-OSE_Labeled_AE
were O
reported O
in O
56 O
% O
of O
randomized O
pediatric O
patients O
in O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
and O
in O
50 O
% O
of O
adult O
patients O
in O
Study O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
I O
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
were O
reported O
more O
frequently O
for O
patients O
who O
received O
every O
8-week O
as O
opposed O
to O
every O
12-week O
infusions O
( O
74 O
% O
and O
38 O
% O
, O
respectively O
) O
, O
while O
serious O
infections B-OSE_Labeled_AE
were O
reported O
for O
3 O
patients O
in O
the O
every O
8-week O
and O
4 O
patients O
in O
the O
every O
12-week O
maintenance O
treatment O
group O
. O

The O
most O
commonly O
reported O
infections B-NonOSE_AE
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
pharyngitis B-OSE_Labeled_AE
, O
and O
the O
most O
commonly O
reported O
serious O
infection B-NonOSE_AE
was O
abscess B-OSE_Labeled_AE
. O

Pneumonia B-OSE_Labeled_AE
was O
reported O
for O
3 O
patients O
, O
( O
2 O
in O
the O
every O
8-week O
and O
1 O
in O
the O
every O
12-week O
maintenance O
treatment O
groups O
) O
. O

Herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
was O
reported O
for O
2 O
patients O
in O
the O
every O
8-week O
maintenance O
treatment O
group O
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
18 O
% O
of O
randomized O
patients O
experienced O
1 O
or O
more O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
with O
no O
notable O
difference O
between O
treatment O
groups O
. O

Of O
the O
112 O
patients O
in O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
there O
were O
no O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
2 O
patients O
had O
non-serious O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
in O
which O
all O
patients O
received O
stable O
doses O
of O
6-MP O
, O
AZA O
, O
or O
MTX O
, O
excluding O
inconclusive O
samples O
, O
3 O
of O
24 O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

Although O
105 O
patients O
were O
tested O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
, O
81 O
patients O
were O
classified O
as O
inconclusive O
because O
they O
could O
not O
be O
ruled O
as O
negative O
due O
to O
assay O
interference O
by O
the O
presence O
of O
infliximab O
in O
the O
sample O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
up O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
were O
seen O
in O
18 O
% O
of O
pediatric O
patients O
in O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
clinical O
trials O
; O
4 O
% O
had O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=3 O
* O
ULN O
, O
and O
1 O
% O
had O
elevations O
> O
=5 O
* O
ULN O
. O

( O
Median O
follow-up O
was O
53 O
weeks O
. O
) O

Pediatric O
Ulcerative O
Colitis O
Overall O
, O
the O
adverse O
reactions O
reported O
in O
the O
pediatric O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
trial O
and O
adult O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
( O
Study O
UC O
I O
and O
Study O
UC O
II O
) O
studies O
were O
generally O
consistent O
. O

In O
a O
pediatric O
UC O
trial O
, O
the O
most O
common O
adverse O
reactions O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

Infections B-OSE_Labeled_AE
were O
reported O
in O
31 O
( O
52 O
% O
) O
of O
60 O
treated O
patients O
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
and O
22 O
( O
37 O
% O
) O
required O
oral O
or O
parenteral O
antimicrobial O
treatment O
. O

The O
proportion O
of O
patients O
with O
infections B-OSE_Labeled_AE
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
was O
similar O
to O
that O
in O
the O
pediatric O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
study O
( O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
) O
but O
higher O
than O
the O
proportion O
in O
the O
adults O
' O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
studies O
( O
Study O
UC B-Not_AE_Candidate
I O
and O
Study O
UC B-Not_AE_Candidate
II O
) O
. O

The O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
was O
13/22 O
( O
59 O
% O
) O
in O
the O
every O
8 O
week O
maintenance O
treatment O
group O
. O

Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
7/60 O
[ O
12 O
% O
] O
) O
and O
pharyngitis B-OSE_Labeled_AE
( O
5/60 O
[ O
8 O
% O
] O
) O
were O
the O
most O
frequently O
reported O
respiratory B-NonOSE_AE
system I-NonOSE_AE
infections I-NonOSE_AE
. O

Serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
12 O
% O
( O
7/60 O
) O
of O
all O
treated O
patients O
. O

In O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
, O
58 O
patients O
were O
evaluated O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
using O
the O
EIA O
as O
well O
as O
the O
drug-tolerant O
ECLIA O
. O

With O
the O
EIA O
, O
4 O
of O
58 O
( O
7 O
% O
) O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

With O
the O
ECLIA O
, O
30 O
of O
58 O
( O
52 O
% O
) O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
, O
Immunogenicity B-NonOSE_AE
( O
6.1 O
) O
] O
. O

The O
higher O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
by O
the O
ECLIA O
method O
was O
due O
to O
the O
60-fold O
higher O
sensitivity O
compared O
to O
the O
EIA O
method O
. O

While O
EIA-positive O
patients O
generally O
had O
undetectable O
trough O
infliximab O
concentrations O
, O
ECLIA-positive O
patients O
could O
have O
detectable O
trough O
concentrations O
of O
infliximab O
because O
the O
ECLIA O
assay O
is O
more O
sensitive O
and O
drug-tolerant O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
up O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
were O
seen O
in O
17 O
% O
( O
10/60 O
) O
of O
pediatric O
patients O
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
; O
7 O
% O
( O
4/60 O
) O
had O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=3 O
* O
ULN O
, O
and O
2 O
% O
( O
1/60 O
) O
had O
elevations O
> O
=5 O
* O
ULN O
( O
median O
follow-up O
was O
49 O
weeks O
) O
. O

Overall O
, O
8 O
of O
60 O
( O
13 O
% O
) O
treated O
patients O
experienced O
one O
or O
more O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
4 O
of O
22 O
( O
18 O
% O
) O
patients O
in O
the O
every O
8-week O
treatment O
maintenance O
group O
. O

No O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
reported O
. O

In O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
, O
45 O
patients O
were O
in O
the O
12 O
to O
17 O
year O
age O
group O
and O
15 O
in O
the O
6 O
to O
11 O
year O
age O
group O
. O

The O
numbers O
of O
patients O
in O
each O
subgroup O
are O
too O
small O
to O
make O
any O
definitive O
conclusions O
about O
the O
effect O
of O
age O
on O
safety O
events O
. O

There O
were O
higher O
proportions O
of O
patients O
with O
serious O
adverse O
events O
( O
40 O
% O
vs O
. O
18 O
% O
) O
and O
discontinuation O
due O
to O
adverse O
events O
( O
40 O
% O
vs O
. O
16 O
% O
) O
in O
the O
younger O
age O
group O
than O
in O
the O
older O
age O
group O
. O

While O
the O
proportion O
of O
patients O
with O
infections B-OSE_Labeled_AE
was O
also O
higher O
in O
the O
younger O
age O
group O
( O
60 O
% O
vs O
. O
49 O
% O
) O
, O
for O
serious O
infections B-OSE_Labeled_AE
, O
the O
proportions O
were O
similar O
in O
the O
two O
age O
groups O
( O
13 O
% O
in O
the O
6 O
to O
11 O
year O
age O
group O
vs O
. O
11 O
% O
in O
the O
12 O
to O
17 O
year O
age O
group O
) O
. O

Overall O
proportions O
of O
adverse O
reactions O
, O
including O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
were O
similar O
between O
the O
6 O
to O
11 O
and O
12 O
to O
17 O
year O
age O
groups O
( O
13 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
Adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
REMICADE O
in O
adult O
and O
pediatric O
patients O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
following O
adverse O
reactions O
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
during O
post-approval O
use O
of O
REMICADE O
: O
neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
, O
agranulocytosis B-OSE_Labeled_AE
( O
including O
infants O
exposed O
in O
utero O
to O
infliximab O
) O
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
/ O
interstitial B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
and O
rapidly O
progressive O
disease O
) O
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
and O
cutaneous O
vasculitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
such O
as O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
inflammatory I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
, O
and O
multifocal B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
) O
, O
new O
onset O
and O
worsening B-OSE_Labeled_AE
psoriasis I-OSE_Labeled_AE
( O
all O
subtypes O
including O
pustular O
, O
primarily O
palmoplantar O
) O
, O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
and O
neuropathies B-OSE_Labeled_AE
( O
additional O
neurologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
also O
been O
observed O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
and O
cholestasis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
serious O
infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
malignancies B-OSE_Labeled_AE
, O
including O
melanoma B-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
and O
cervical B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
and O
vaccine B-NonOSE_AE
breakthrough I-NonOSE_AE
infection I-NonOSE_AE
including O
bovine B-NonOSE_AE
tuberculosis I-NonOSE_AE
( O
disseminated B-NonOSE_AE
BCG I-NonOSE_AE
infection I-NonOSE_AE
) O
following O
vaccination O
in O
an O
infant B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
in I-OSE_Labeled_AE
utero I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Infusion-related O
Reactions O
In O
post-marketing O
experience O
, O
cases O
of O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
laryngeal B-OSE_Labeled_AE
/pharyngeal O
edema I-OSE_Labeled_AE
and O
severe O
bronchospasm B-OSE_Labeled_AE
, O
and O
seizure B-OSE_Labeled_AE
have O
been O
associated O
with O
REMICADE O
administration O
. O

Cases O
of O
transient B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
REMICADE O
during O
or O
within O
2 O
hours O
of O
infusion O
. O

Cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia/ O
infarction I-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
, O
and O
arrhythmia B-OSE_Labeled_AE
occurring O
within O
24 O
hours O
of O
initiation O
of O
infusion O
have O
also O
been O
reported O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Adverse O
Reactions O
in O
Pediatric O
Patients O
The O
following O
serious O
adverse O
reactions O
have O
been O
reported O
in O
the O
post-marketing O
experience O
in O
children O
: O
infections B-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
including O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
and O
tuberculosis B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
in O
the O
post-marketing O
experience O
with O
REMICADE O
in O
the O
pediatric O
population O
have O
also O
included O
malignancies B-OSE_Labeled_AE
, O
including O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphomas I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
transient O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
and O
the O
development O
of O
autoantibodies B-OSE_Labeled_AE
. O

